Stage III Non-small Cell Lung Cancer Resectability in a Country With Limited Diagnostic and Therapeutic Resources: A Colombian Expert Consensus
Cancer Control · 2026-06 · 33
DOI: 10.1177/10732748261457714 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Control, online erschienen am 06.06.2026. Verfasst von Carlos A Carvajal und 20 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center - CTIC, Bogotá, Colombia. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Introduction
The role of surgery in stage III non-small cell lung cancer (NSCLC), particularly in the presence of ipsilateral mediastinal lymph node involvement (N2), remains controversial. Criteria for resectability differ among existing clinical guidelines and are particularly difficult to apply in countries with limited access to advanced diagnostic and therapeutic resources. Accordingly, this Colombian expert consensus aimed to define resectability criteria for stage III NSCLC within real-world resource-limited contexts.
Methods
This expert consensus statement was developed by a multidisciplinary panel of Colombian experts following the European Society for Medical Oncology (ESMO) Standardized Operating Procedures. A structured literature review was conducted to inform structured clinical questions addressing resectability across different stage III NSCLC scenarios. Recommendations were formulated through iterative discussion and anonymous voting, with levels of evidence and grades of recommendation assigned according to ESMO methodology.
Results
Consensus was achieved for resectability in selected scenarios of single-station, non-bulky N2 disease, particularly in T1–2 tumors and T3 satellite lesions. Multi-station or bulky N2 disease was more frequently classified as potentially resectable in T1-2 tumors, with greater variability in expert agreement. For T4 disease, resectability depended on the pattern of invasion, nodal burden, and the feasibility of complete resection within a multimodality treatment strategy. Invasive restaging after induction therapy was strongly supported in selected scenarios. Across all recommendations, the panel emphasized the importance of multidisciplinary evaluation and individualized decision-making.
Conclusions
This consensus provides practical, context-specific recommendations on the resectability of stage III NSCLC in settings with limited diagnostic and therapeutic resources. By integrating available evidence with expert judgment, these recommendations aim to support multidisciplinary teams in selecting appropriate candidates for surgical management as part of multimodality therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Thoracic Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center - CTIC, Bogotá, Colombia.
- Thoracic Oncology Unit, Instituto Nacional de Cancerología - INC, Bogotá, Colombia.
- Thoracic Surgery Unit, Clínica Portoazul - AUNA, Barranquilla, Colombia.
- Thoracic Surgery Department, Organización Clínica General del Norte, Barranquilla, Colombia.
- Thoracic Surgery Unit, Fundación Valle del Lili, Cali, Colombia.
- Thoracic Surgery Unit, Hospital Pablo Tobón Uribe, Medellín, Colombia.
ORCID-Profile: Carlos A Carvajal, Stella I Martínez, Diego Pardo, Darwin Padilla, Mauricio Velásquez, Willfredy Castaño, Fernando Alvarado, Ricardo A Zapata-González, Jairo Zuluaga, Ricardo E Bruges, Leonardo Rojas, Lucia Viola, Ana M Callejas, Alejandro González-Motta, Eduardo Guerrero, Fernando Rodríguez, José R Pieschacón, Natalia Sánchez, Andrés F Cardona
Förderung
- AstraZeneca
Zitieren
APA
Carvajal, C. A., Martínez, S. I., Pardo, D., Padilla, D., Velásquez, M., Castaño, W., Alvarado, F., Zapata-González, R. A., Zuluaga, J., Bruges, R. E., Rojas, L., Zuluaga, C., Viola, L., Callejas, A. M., González-Motta, A., Guerrero, E., Rodríguez, F., Pieschacón, J. R., Nicolle, W. G., …, & Cardona, A. F. (2026). Stage III Non-small Cell Lung Cancer Resectability in a Country With Limited Diagnostic and Therapeutic Resources: A Colombian Expert Consensus. Cancer Control, 33. https://doi.org/10.1177/10732748261457714
Vancouver
Carvajal CA, Martínez SI, Pardo D, Padilla D, Velásquez M, Castaño W, et al. Stage III Non-small Cell Lung Cancer Resectability in a Country With Limited Diagnostic and Therapeutic Resources: A Colombian Expert Consensus. Cancer Control. 2026;33. doi:10.1177/10732748261457714
BibTeX
@article{Carvajal2026,
author = {Carvajal, Carlos A and Martínez, Stella I and Pardo, Diego and Padilla, Darwin and Velásquez, Mauricio and Castaño, Willfredy and Alvarado, Fernando and Zapata-González, Ricardo A and Zuluaga, Jairo and Bruges, Ricardo E and Rojas, Leonardo and Zuluaga, Clarena and Viola, Lucia and Callejas, Ana M and González-Motta, Alejandro and Guerrero, Eduardo and Rodríguez, Fernando and Pieschacón, José R and Nicolle, Wagner-Gutiérrez and Sánchez, Natalia and Cardona, Andrés F},
title = {Stage III Non-small Cell Lung Cancer Resectability in a Country With Limited Diagnostic and Therapeutic Resources: A Colombian Expert Consensus},
journal = {Cancer Control},
year = {2026},
volume = {33},
doi = {10.1177/10732748261457714}
}
EUVIMED